Bartlett JG, Redfield RR, and Pham PA. 2013 Medical Management of HIV Infection International Edition. Knowledge Source Solutions LLC, Durham, NC.

  1. Bartlett JG, Redfield RR, Pham PA, and Ojoo S. 2013 Medical Management of HIV Infection Kenya Edition. Knowledge Source Solutions LLC, Durham, NC.
  2. Bartlett JG, Redfield, RR, Pham PA, Mazus AI. 2013 Medical Management of HIV Infection Russian Edition.
  3. Redfield R R. Imported Nosocomial Viral Diseases: Rabies and Hemorrhagic Fever. J. Nosocomial Infection, 1985; 2: 6-14.
  4. Redfield R R. HIV Infection Monograph. Abbott Laboratories, 1985.
  5. Kelley PW, Takafuji ET, Tramont EC, Redfield R R, Brudndage JF, Herbold J and Miller RN. The Importance of HIV Infection for the Military in AIDS and Other Manifestations of HIV Infections. (Editors: Ubrmser GP, Stahl RE and Bottone EJ) Noyes Publications, Park Ridge, NJ, 1987; p 67-85.
  6. Looney W, Redfield R R. HTLV Retroviruses and Transfusion Transmitted Diseases. S.J. Insalaco and J. E. Menitove eds. Transfusion Transmitted Viruses: Epidemiology and Pathology Arlington, VA: American Association of Blood Banks1987; 131-153.
  7. Redfield R R. Burke D. HIV Infection: The Clinical Picture. Scientific American 1988; 90-98.
  8. Brundage JF, Burke DS, Gardner LI, Visintine R, Peterson M, Redfield RR. HIV Infection among young adults in the New York City area, Prevalence and incidence estimates based on antibody screening among civilian applicants for military service. Acquired Immunodeficiency Syndrome 1989, Chapter 8, 39-42.
  9. Redfield R R. HIV Vaccine Therapy: Augmenting the Body's Inadequate Immune Response.HIV Advances in Research and Therapy - Cliggott Publishing Co., 1993; 3-7.
  10. Birx DL, Redfield R R. Therapeutic HIV Vaccines: Concept, Current Status, and Future Direction. Textbook of AIDS Medicine. Ed. Broder S, Merigen T, Bolognesi D. Williams & Wilkins 1994; 45: 693-711.
  11. Redfield R R, Blattner WA, Gallo RC,. HIV at the Millennium; Introduction to Textbooks of AIDS Medicine (Broder S, Merigan TC, Bolognesi D, eds.) 1999.
  12. Lambert JS, Redfield R R, Tramont EC.. Therapeutic HIV Vaccines: Concept, Current, Status, and Future Directions. Antiretroviral Therapy, ASM Press, 2001.
  13. Amoroso A, Davis CE, Redfield R R. The Role of Antiretroviral Therapy in Africa. AIDS In Africa, Kluwer Academic/Plenum Publishers, 2002.
  14. Gilliam BL, Amoroso A, Davis CE, Redfield RR. The Role of Antiretroviral Therapy in Asia.AIDS In Asia, Kluwer Academic/Plenum Publishers, 2004.

Journal Articles


  1. Goodman SC, Galati SC, Redfield R R, Spiegleman S. Room Temperature Chromatograph of Nucleic Acids on Hydroxylaptite Columns in the Presence of Formamide. Analytical Biochemistry 1973; 52 (1): 286-299.
  2. Sweet RW, Goodman NC, Cho JR, Rurrecht RNI, Redfield R R, Spiegleman S. The Presence of Unique DNA Sequences After Viral Introductrion of Leukemia in Mice. Proc Nat Acad Sci. 1974; 71(5):1705-1709.
  3. Via C, Hasbargen J, Moore J, Redfield R R, Antonovych T. Rheumatoid Arthritis and Membraneous Glomerulonephritis: A Role for Immune Complex Dissociative Techniques. J Rheumatol 1984, 11(3): 342-347.
  4. Gallo RC, Salahuddin SZ, Popic V, Shearer GM, Kaplan M, Hayes BF, Palker,TJ, Redfield R R, Oleske J, Saai B, White G, Foster P, Markham, PD. Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS. Science 1984; 224: 500-502.
  5. Binn LN, Lemon SM, Marchwicki RH, Redfield R R, Gates NL, Bancroft WH. Primary Isolation and Serial Passage of Hepatitis A Virus Strains in Primate Cell Cultures. J. Clin. Micro. 1984; 20(1): 28-38.
  6. Salahuddin SZ, Groopman JE, Markham PD, Sarngadharan MG, Redfield R R, McLane MF, Essex M, Sliski A, Gallo RC. HTLV-III in Symptom-Free Seronegative Persons. Lancet 1984; 2(8417-18):1418-1420.
  7. Redfield R R, Markham PD, Salahuddin SZ, Sarngadharan MG, Bodner AJ, Folks TM, Ballou WR, Wright DC, Gallo RC. Frequent Transmission of HTLV-III Among Spouses of Patients with AIDS-Related Complex and AIDS. JAMA 1985; 253(11):1571-1573.
  8. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield R R, Field ML, Kelley PW. Frequency of Illness Associated with Epidemic Hepatitis A Virus Infections in Adults. Am J Epidemiol 1985; 122(2): 226-233.
  9. James WD, Redfield R R, Lupton GP, Meltzer MS, Berger TG, Rodman OG, Markham PD, Sarngadharan MG, Salahuddin SZ, Gallo RC. A Popular Eruption Associated with Human T Cell Lymphotropic Virus Type III Disease. J Am Acad Dermatol 1985; 13(4): 563-566.
  10. Wong-Staal F, Shaw GM, Hahn BH, Salahuddin SZ, Popovic M, Markham P, Redfield R R, Gallo RC. Genomic Diversity of Human T-Lymphotropic Virus Type III (HTLV-III), Science 1985: 229 (4715): 759-762.
  11. Redfield R R, James WD, Wright CD, Brown C, Salahuddin SZ, Markham PD, Sarngadharan MG, Folks TF, Gallo RC. Severe Molluscum Contagiosum Infection in a Patient with Human T-Cell Lymphotropic (HTLV-III) Disease. J. Am. Acad Dermatol 1985; 13(5 Pt 1): 821-824.
  12. Broder S, Collins JM, Markham PD, Redfield R R, Hoth DF, Groopman JE, Gallo RC, Yarchoan RH, Lane HC, Klecker RW, Mitsuya H, Glemann E, Resnick L, Myers CE, Fauci AS. Effects of Suramin on HTLV-III/LAV Infection Presenting as Kaposi’s Sarcoma or AIDS- Related Complex: Clinical Pharmacology and Suppression of Virus Replication in Vivo. Lancet 1985; 2(8456): 627-630.
  13. Redfield R R, Markham PD, Salahuddin SZ, Wright DC, Sarngadharan MG, Gallo RC. Heterosexually Acquired HTLV III/LAV Disease (AIDS-Related Complex and AIDS). JAMA 1985; 254 (15); 2094-2096.
  14. Lightfoote M, Folks TM, Redfield RR, Gold J, Sell K. Circulating IgA immune complexes in AIDS. Immunological Investigations 1985, 14(4)341-345
  15. Redfield R R, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical Evaluation of Low- Dose Intradermally Administered Hepatitis B Virus Vaccine. JAMA, 1985. 254(22): 3204-3206.
  16. Collins JM, Klecker RW Jr, Yarchoan R, Lane HC, Fauci AS, Redfield R R, Broder S, Myers CE. Clinical Pharmacokinetics of Suramin in Patients with HTLV-III/LAV Infection, J Clin Pharmacology: 1986; 266 (1):22-26.
  17. Redfield R R, Wright DC, Tramont EC. The Walter Reed Staging Classification for HTLV- III, LAV Infection. N Engl J Med 1986; 314: 131-132.
  18. Lightfoote M, Folks T, Redfield RR, Gold J, Marti GE, Kelly J, Sell KW. Flow cytometry detection of circulating immune complexes. Journal of Immunological Methods 1986; 95(1), 107-112
  19. Redfield R R. Female to Male Transmission of HTLV-III (Letter). JAMA 1986; 255: 1705- 1706.
  20. Birx DL, Redfield R R, Tosato G. Defective Regulation of Eepstein-Barr Virus Infection in Patients with Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Disorders. N Engl J. Med. 1986; 314 (14): 874-879.
  21. Gardner LI Jr, Redfield R R, Lednar WM, Lemon SM, Miller RN. Occupational and Geographic Risk Factor for Hepatitis B Among US Army Enlisted Personnel During 1980. Am J Epidemiol 1986; 123 (3): 464-472.
  22. Yarchoan R, Redfield R R, Broder S. Cell Activation in Patients with HTLV-III/LAV Infection: Contribution of B Cells, and of HTLV-III/LAV-Induced Immunoglobulin Production. J Clin Invest 1986; 78 (2): 439-447.
  23. Shearer GM, Berstein DC, Tung KSK, Via CS, Redfield R R, Salahuddin SZ, Gallo RC. A Model for Selective Loss of Major Histocompatibility Complex Self-Restricted T-Cell Immune Responses During the Development of Acquired Immune Deficiency Syndrome (AIDS). J Immunology 1986; 137 (8): 2514-2521.
  24. Hahn BH, Shaw GM, Taylor ME, Redfield R R, Markham PD, Salahuddin SZ, Wong-Staal F, Gallo RC, Parks ES, Parks WP. Genetic Variation in HTLV-III/LAV Overtime in Patients with AIDS or at Risk for AIDS. Science 1986; 232(4757): 1548-1553.
  25. Burke DS, Redfield R R. False Positive Western Blot Tests for Antibodies to HTLV-III (Letter). JAMA 1986; 256 (3): 347.
  26. Cohen IS, Anderson DW, Virmani R, Reen BM, Macher AM, Sennesh J, DiLorenzo P,  Redfield R R. Congestive Cariomyopathy in Association with the Acquired Immunodeficiency Syndrome. N Engl J Med. 1986; 315 (10): 628-630.
  27. Kelley PW, Redfield R R, Ward DL, Burke DS, Miller RN. Prevalence and Incidence of HTLV-III Infection in a Prison (Letter). JAMA 1986; 256 (16): 2198-2199.
  28. Redfield R R, Wright DG, Tramont EC, The Walter Reed Staging Classification in Follow Up of HIV Infection (Letter reply). N Engl J Med. 1986 315:1356.
  29. Weber W, Redfield R R, Lemon SM. AIDS: Epidemiology and Significance for the Obstetricianand Gynecologist. Amer J of OB Gyn 1986: 155 (2): 235-240.
  30. Bender BS, Auger FA, Quinn TC, Redfield R R, Gold J, Folks TM. Impaired Antibody Dependent Cell-Mediated Cytotoxic Activity in Patients with the Acquired mmunodeficiency Syndrome. Clin Exp Immunol 1986; 64 (1): 166-172.
  31. Folks T, Kelly J, Benn S, Kinter A, Justment J, Gold J, Redfield R R, Sell KW, Fauci AS. Susceptibility of Normal Human Lymphocytes to Infection with HTLV-III/LAV. J Immunol 1986; 136 (11): 4049-4053.
  32. Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein Barr virus infection in patients with AIDS or AIDS related disorders (letter reply) N Engl J Med. 1986; 315 (12), 762
  33. Redfield RR. Heterosexual transmission of human T lymphotropic virus type III: syphilis revisited. The Mount Sinai Journal of Medicine, New York 1986; 53(8), 592
  34. Collins JM, Klecker RW, Yarchoan R, Lane HC, Fauci AS, Redfield RR, Broder S, Myers CE. Clinical Pharmacokinetics of Suramin in Patients with HTLV-III/LAV Infection. J Clin Pharmacol 1986; 26:22-26
  35. Redfield R R, Wright DC, Lemon WD, Brown C, Burke DS. Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease. N Engl J Med 1987; 316 (11): 673-676.
  36. Burke DS, Redfield R R, Putnam P, Alexander SS. Variations in Western Blot Banding Patterns of Human T-Cell Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus.  J Clin Micro 1987; 25 (1): 81-84.
  37. Shanks DG, Redfield R R, Fischer GW. Toxoplasma Encephalitis in an Infant with AIDS. J Peds Inf Dis. 1987; 6 (1): 70-71.
  38. McKee KT, Bancroft WH, Eckels KH, Redfield R R, Russell PK. Lack of Attenuation of a Candidate Dengue I Vaccine (4SAZS) in Human R. Volunteers. Amer J Trop Med Hyg. 1987; 36 (2): 435-442.
  39. Burke, DS, Brandt BL, Redfield R R, Lee Tun-Hou, Thorn RM, Beltz GA, Hung Chung-Ho.Diagnosis of Human Immunodeficiency Virus Infection by Immunoassay Using a Molecularly Cloned and Expressed Virus Envelope Polypeptide. Annal of Int Med. 1987; 106 (5): 671-676.
  40. Redfield R R, Burke DS. Classification of HTLV-III/LAV Infections (Letter). Ann of Int Med. 1987; 106:97.
  41. Redfield R R, Burke DS. Shadow on the Land - The Epidemiology of HIV. Viral Immunol.1987; 1 (1): 69-81.
  42. Rhoads JL, Wright DC, Redfield R R, Burke DS. Chronic Vaginal Candidates in Women with HTLV Infection. JAMA 1987; 257 (22): 3105-3107.
  43. Burke DS, Brundage JF, Herbold J, Berner W, Gardner LI, Gunzenhauser JD, Voskovitch J, Redfield R R. Human Immunodeficiency Virus Infections Among Civilian Applicants for Military Service. October 1985 to March 1986. N Engl J Med. 1987; 317 (3): 131-136.
  44. Lennox JF, Redfield R R, Burke DS. HIV Antibody Screening in a General Hospital Population (Letter). JAMA 1987; 257: 1914.
  45. Lupton GP, James WD, Redfield R R, Brown C, Rodman OG. Oral “Hairy” Leukoplakia - A Distinctive Marker of Human T- Lymphotropic Virus Type III (HTLV-III) Disease. Arch Dermatol. 1987; 123 (5): 624-628.
  46. Kanki PJ, Allan J, Barin F, Quinn T, Clumeck N, Thirty L, Burny A, Redfield RR, Essex M. Absence of HTLV-IV in Six Central African Nations, AIDS Res Hum Retroviruses 1987; 13: 7- 12.
  47. James WD, Redfield, RR. Human Immunodeficiency and Skin Disease. J Assoc. Mil Derm.1987; 13: 7-12.
  48. Tramont EC, Redfield RR, Burke D, Takafuji ET, Wright C, Moore W. HTLV-III/LAV infections in the military. Military Medicine 1987; 152(2), 105
  49. Looney DJ, Fisher AG, Putney SD, Rusche JR, Redfield R R, Burke DS, Gallo RC, Won-Stall
  50. F. Type-Restricted Neutralization of Molecular Clones of Human Immunodeficiency Virus. Science 1988; 241 (4863): 357-59.
  51. Brundage JF, Burke DS, Gardner LI, Visintine R, Peterson M, Redfield R R. HIV Infection Among Young Adults in the New York City Area: Prevalence and Incidence Estimates Based on Antibody Screening Among Civilian Applicants for Military Service. New York State J Med. 1988; 88 (5): 232-235.
  52. Burke DS, Brundage JF, Redfield R R, Damato JJ, Schable CA, Putnam P, Visitine R, Kim HI. Measurement of the False Positive Rate in a Screening Program for Human Immunodeficiency Virus Infections. N Engl J Med. 1988; 319: 961-964.
  53. Burke DS, Redfield R R. Transmission of Human Immunodeficiency Virus (HIV). N Engl J Med. (letter) 1988 318: 1202-1203.
  54. Burke DS, Redfield RR. Clinical importance of HIV antigens and anti-HIV core markers in persons infected with HIV (letter). N Engl J Med. 1988; 318 (18), 1202-1203
  55. Matsuda Z, Chou M, Matsuda M, Huand JH, Chen M, Redfield R R, Mayer K, Essex M, Lee TH. Human Immunodeficiency Virus Type I Has an Additional Coding Sequence in the Central Region of the Genome. Proc Natl Acad Sci. USA 1988; 85 (18): 6968-6972.
  56. Damato JJ, Fipps DR, Redfield R R, Burke DS. The Department of the Army Quality Assurance Program for Human Immunodeficiency Virus Antibody Testing. Virology 1988; 19: 577-580.
  57. Malik IA, Legters LJ, Lugman M, Ahmed A, Redfield R R. The Serological Markers of  Hepatiti A and B in a Healthy Population in Northern Pakistan. J Pakistan Med Assoc. 1988; 38 (3): 69-72.
  58. Shafferman A, Lennox J, Grosfeld H, Sadoff G, Redfield R R, Burke DS. Patterns of  Antibody Recognition of Selcted Conserved Amino Acid Sequences from the HIV Envelope in Sera from Different Stages of HIV Infection. AIDS Res Human Retrovir 1989; 5 (1): 33-39.
  59. Redfield R R, Tramont EC. Toward a Better Classification System for HIV Infection (Editorial). N Engl J Med. 1989; 320 (21): 1414-1416.
  60. Burke DS, Redfield R R, Bjorrnson DC, Fowler AK, Oster CN. Frequent Isolation of HIV-1 from the Blood of Patients Receiving Zidovudine (AZT) Therapy (Letter). N England J Med. 1989; 3-1 (24): 1682.
  61. Burke DS, Brundage JF, Redfield RR, Damato JJ. Screening for human immunodeficiency virus infections (Letter reply) N Engl J Med. 1989; 320 (7) 462-463
  62. Brundage JF, McNeil JG, Miller RN, Gardner LI Jr, Harrison SM, Hawks C, Craici DB, Redfield R R, Burke DS. The Current Distribution of CD4+ T-Lymphocyte Counts Among Adults in the United States with Human Immuno-deficiency Virus Infections: Estimates Based on the Experience of the U.S. Army. J Acquir Immune Defic Syndr. 1990; 3 (8): 92-94.
  63. Tramont EC, Redfield R R. Soluble CD4: The Frist Step (Editorial Comment).Ann Intern Med. 1990; 112: 241-242.
  64. Burke DS, Brundage JF, Goldenbaum M, Gardner LI, Redfield R R. Human Immunodeficiency Virus Infections in Teenagers. Seroprevalence Among Applicants for U.S. Military Service. JAMA 1990; 263 (15): 2074-77.
  65. Looney JL, Hayashi S, Nicklas M, Redfield R R, Broder S,Wong-Staal F,Mitsuva H. Differences in the interaction of HIV-1 and HIV-2 with CD4.J Acquir Immune Defic Syndr 1990; 3 (7): 649-657.
  66. Birx DL, Redfield R R, Tencer K, Fowler AK, Burke DS, Tosato G. Induction of IL-6 During HIV Infection. Blood 1990; 76:2303-2310.
  67. Burke DS, Fowler AK, Redfield R R, Dilworth S, Oster CN. Isolation of HIV-1 from the Blood of Seropositive Adults. J Acquir Immune Defic Syndr. 1990; 3 (12): 1159-1167.
  68. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield R R. Immunologic Parameters in Early Stage HIV Seropositive Subjects Associated with Vaccine Responsiveness. J Acquir Immune Defic Syndr. 1991; 4 (2): 188-196.
  69. Brundage JF, Burke DS, Gardner LI, McNeil JM, Goldenbaum M, Visintine R, Redfield R R, Peterson M, Miller RN. Tracking the Spread of the HIV Infection Epidemic Among Young Adults in the U.S.: Results of the First Four Years of Screening Among Civilian Applicants for U.S. Military Service. J Acquir Immune Defic. 1991; 3 (12): 1168-1180.
  70. Birx DL, Redfield RR. HIV Vaccine Therapy. International Journal of Immunopharmacology 1991; 13, 129-132
  71. Burke DS, Brundage JF, Redfield R R, Tramont EC. Response to “Mandatory HIV Testing and the Duty to Screen” (Editorial Comment). Military Medicine 1991; May 1991.
  72. Wages JM, Hamdallah M, calabro MA, Fowler AK, Oster CN, Redfield R R, Burke DS. Clinical Performance of a Polymerase Chain Reaction Testing Algorithm for Diagnosis of HIV- 1 Infection in Peripheral Blood Mononuclear Cells. J. Med Virology 1991; 33: 58-63.
  73. Michael N, Morrow P, Mosca J, Vahey MT, Burke DS, Redfield R R. Induction of HIV-1 Expression in Chronically Infected Cells is Associated Primarily with a Shift in RNA Spacing Patterns. J Virology 1991: 65 (7084).
  74. Damato JJ, O’Bryen BN, Fuller SA, Roberts CR, Redfield R R, Burke DS. Resolution of Indeterminate HIV-1 Test Data Using the Department of Defense HIV-1 Testing Program. Lab Med. 1991; 2: 107-113.
  75. Redfield R R, Birx DL, Ketter N, Polonis V, Davis C, Smith G, Johnson S, Fowler A, Brundage JF, Wierzba T, Shafferman A, Volvovitz F, Oster C, Tramont EC, Burke DS. HIV Vaccine Therapy Phase I Safety and Immunogenicity Evaluation of Post Infection Immune Modification by Active Immunization with Recombinant GP 160. N Eng J Med.1991; 324: 1677-1684.
  76. McNeil JG, Brundage JF, Gardner LI, Wann Zf, Renzzullo PO, Redfield R R, Burke DS, Miller RN. Trends of Human Immunodeficiency Virus Seroconversion Among Young Adults in the U.S. Army 1985 to 1989. JAMA 1991; 265 (13): 1709-1714.
  77. Di Giovanni C, Berlin F, Casterella P, Redfield R R, Hiken M, Falck A, Malin HM, Gagaliano S, Schaerf F, Roberts C. Prevalence of HIV Antibody Among a Group of Paraphilic Sex Offenders. J Acquir Immune Defic Syndr. 1991; 4 (6): 633-637.
  78. Polonis V, Anderson G, Vahey MT, Morrow PJ, Stoler D, Burke D, Redfield R R. Anoxia Induces Human Immunodeficiency Virus Expression in Infected T Cells Lines. J of Biological Chem. 1991; 266 (18): 1142-1144.
  79. Rhoads JL, Birx DL, Wright DC, Brundage JF, Brandt BL, Redfield R R, Burke DS. Safety  and Immunogenicity of Multiple Conventional Immunizations Administered During Early HIV Infection. J Acquir Immune Defic Syndr. 1991; 4 (12): 724-731.
  80. McCutchan FE, Sanders-Buell E, Oster CW, Redfield R R, Burke DS. Genetic Comparison   of HIV-1 Isolates by Polymerase Chain Reaction. J Acquir Immune Defic Syndr. 1991; 4: 1241- 1250
  81. VanCott TC, Loomis LD, Redfield R R, Birx DL. Real-Time Biospecific Interaction Analysis of Antibody Reactivity to Peptides from the Envelope Glycoprotein GP 160 of HIV-1. J of Immunological Methods 1992; 146: 163-170.
  82. Michael NL, Vahey M, Burke DS, Redfield R R. Viral DNA and mRNA Expression Correlate with the State of Human Immunodeficiency Virus (HIV) Type 1 Infection in Humans:   Evidence for Viral Replication in all Stages of HIV Disease. J of Virology 1992; 66 (1): 310-  316.
  83. Hamilton JD, Hartigan PM, Simberkoff MS, and the Veterans Affairs Cooperative Study Group on Aids Treatment (Redfield R R et al). A Controlled Trial of Early Versus Late Treatment with Zidovudine in Symtomatic Human Immunodeficiency Virus Infection. N Engl J Med. 1992; 326 (7): 437-468.
  84. Redfield R R, Birx DL. HIV Specific Vaccine Therapy: Concepts, Status and Future Directions. AIDS Res & Human Retro 1992; 8 (6): 1051-1058.
  85. Redfield R R, Birx DL, Tramont EC, Burke DS. Vaccination with gp 160 in HIV. (Letter). N Engl J Med. 1992; 326.
  86. Robb ML, Polonis V, Vahey M, Gartner S, Michael N, Redfield R R. HIV Neutralization Assay Using PCR Derived Molecular Signals. J Acquir Immune Def Syndr. 1992; 5: 1224-1229.
  87. Warren RQ, Nkya WM, Shao JF, Anderson SA, Wolf H, Hendrix CW, Kanda P, Wabuke M, Boswell RN, Redfield R R, Kennedy RC. Comparison of Antibody Reactivity to HIV-1 Epitopes in Sera from HIV-1 Infected Individuals from Tanzania and theUnited States. J Clin Micro 1992; 30: 126-131.
  88. Nyka WM, Warren RQ, Wolf H, Tesha J, Redfield R R, Melcher GP, Burke DS, Kanda P, Kennedy RC. Fine Specificity of the Humoral Response to HIV-1 gp 160 in HIV-1 Infected Individuals from Tanzania. J Med Virol. 1992; 37 (1): 61-65.
  89. Warren RQ, Anderson SA, Nkya WM, Shao JF, Hendrix CW, Melcher GP, Redfield R R, Kennedy RC. Examination of Sera from Human Immunodeficiency Virus Type I (HIV - I) Infected Individuals for Antibodies Reactive with Peptides Corresponding to the Principal Neutralizing Determinant of HIV - 1 gp 120 and for In Vitro Neutralizing Activity. J of Viirology 1992; 66: 5210-5215.
  90. Gardner LI, Brundage JF, McNeil JG, Milazzo MJ, Redfield R R, Aronson NE, Craig DB, Davis C, Gates RH, Levin LI, Michael RA, Oster CN, Ryan WC, Tramont EC, Burke DS. Predictors of HIV Disease Progression in Early and Late Stage Patients: The U.S. Army Natural History Cohort. J Acquir Immune Defic Syndr. 1992; 9: 875-882.
  91. Kim JH. Mosca JD, Vahey MT, McLinden RJ, Burke DS, Redfield R R. Consequences of Human Immunodeficiency Virus Type I Superinfection of Chronically-Infected Cells. AIDS Res Hum Retroviruses. 1993; 9: 875-882.
  92. Simberkoff MS, Hartigan PM, Hamilton JD, Devkin D, Gall MH, Bartlett JG, Feorino PM, Redfield R R, Roberts RB, Collins D, DeMets DL, Pritchett W, Spritz N, Wenzel RP and the VA Cooperative Study Group on AIDS Treatment. Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Studies. Controlled Clin Trials. 1993; 14 (1): 6-18.
  93. Birx DL, Brundage J, Larson K, Engler R, Smith L, Carpenter G, Sullivan M, Rhoads J, Oster   C, James W, Lupton G, Wierzba T, Burke D, Redfield R R. The Prognostic Utility of Delayed Type Hypersensitivity Skin Testing in the Evaluation of HIV Infected Patients. J Acquir Defic Sydrn 1993; 6: 1247-1255.
  94. Birx DL, Redfield R R. Immunotherapeutic Strategies in the Treatment of HIV Infection and AIDS. Current Opinion in Immunol 1993; 5: 600-607.
  95. Levi M, Ruden U, Birx D, Loomis L, Redfield R R, Lovgren K, Akerblom L, Sandstrom E, Wahren B. The effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp 160 of HIV-1. J Acquir Immune Defic Syndr. 1993; 6:994-1085.
  96. Lucey DR, VanCott TC, Loomis LD, Bethke R, Hendrix CW, Melcher GP, Redfield R R, Birx DL. Measurement of cerebrospinal fluid antibody to the HIV-1 principle neutralizing determinant (V3 loop). J Acquir Immune Defic Syndr. 1993; 6: 1073-1085.
  97. Wages JM, Hamdallah M, Fowler AK, Roberts CN, Redfield RR, Burke DS. Clinical performance of non-radioactive assays for HIV-1 DNA amplified by the polymerase chain reaction. World Journal of Microbiology and Biotechnology, 1993; 9, 102-107
  98. Redfield RR, Birx DL. A hypothesis post infection vaccine therapy: a novel strategy for the prevention of HIV infection. 1993 Vaccines, 49.
  99. Michael N, Chang G, Ehrenberg PK, Vahey MT, Redfield R R. HIV-1 Proviral Genotypes from the Peripheral Blood Mononuclear Cells of an Infected Patient are Differentially Represented in Expressed Sequences. J Acquir Immune Defic Syndr 1993; 6:1073-1085.
  100. Birx DL, Lewis M, Vahey M, Tencer K, Zack P, Jahrling P, Tosato G, Burke D, Redfield R R. Association of IL-6 in the Pathogenesis of Acutely Fatal SIV-pbj in Pigtailed Macaques. AIDS Res & Human Retro 1993; 9:1123-1130.
  101. VanCott TC, Bethke FR, Artenstein AW, McCutchan FE, McNeil JG, Mascola JR, Redfield R R, and Birx DL. Serotyping International HIV-1 Isolates by V3 Peptides and Whole GP 160 Proteins Using BIAcore. Methods: A Companion to Methods in Enzymology 1994; 6:188-198.
  102. Biselli R, Loomis LD, Del Bono V, Smith G, Burke DS, Redfield R R, Birx DL. Immunization of HIV-infected patients with rgp160: Modulation of anti-rgp120 antibody spectrotype. J. Acquir. Immune Defic Syndr 1994; 10:1016-1034.
  103. DeFraites R, Smoak B, Trofa A, Hoke C, Kanesa-thasan N, King A, MacArthy P, Putnak J, Burrous J, Oster C, Redfield RR, et al. Dengue fever among US military personnel-Haiti. September-November 1994. MMWR, Vol 43; 845-848
  104. Vahey MT, Birx DL, Michael NL, Burke DS, Redfield R R. Assesment of Viral Load in HIV Infected Patients Receiving Intervention with a Recombinant gp 160 Subunit Vaccine in a Phase One Study. AIDS Res Hum Retroviruses 1994; 10:649-654.
  105. VanCott TC, Bethle FR, Kalyanaraman V, Burke DS, Redfield R R, Birx DL. Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules. J Acquir Immune Defic Syndr 1994; 11: 1103-1115.
  106. Michael NL, Vahey MT, d’Arcy L, Ehrenberg PK, Mosca JD, Rappaport J, Redfield R R. Negative Strand Transcripts are Produced in HIV-1 Infected Cells and Patients by a Novel Promoter Downregulated by Tat.  J of Virology 1994; 68: 979-987.
  107. Burnett P, VanCott TC, Polonis VR, Birx DL, and Redfield R R. Immunoglobulin A- mediated neutralization of human immunodificiency virus type 1. J of Immunology, 1994; 152: 4642-4648.
  108. Kim JH, Ratto S, Sitz KV, Mosca JD, McLinden RJ, Tencer KL, Vahey MT, St. Louis D, Birx DL, Redfield R R. Consequences of stable transduction and antigen inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cells. Human Gene Therapy 1994; 5:1457-1466.
  109. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield R R, Birx DL. The dissociation rate of antibody gp 120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J of Immunology 1994; 153:449-459.
  110. Michael NL, d’Arcy L, Ehrenberg PK, Vahey MT, Birx DL, Redfield R R. 1994. Naturally Occurring Genotypes of the HIV-1 Long Terminal Repeat Display, A Wide Range of Transcriptional Competency. J of Virology  1994; 68:3163-3174.
  111. Ratto S, Sitz KV, Scherer AM, Manca F, Loomis LD, Cox JH, Redfield R R, Birx DL. Establishment and characterization of HIV-1 envelope specific CD4+T-lymphocyte lines from HIV-seropositive patients. J of Infectious Diseases 1995; 171(6):1420-1430.
  112. VanCott TC, Bethke FR, Burke DS, Redfield R R, Birx DL. Lack of antibodies specific for conserved, discontinuous epitopes within sera from human volunteers receiving candidate HIV-1 envelope vaccines. J of Immunology  1995; 155(8):4100-4110.
  113. Michael NL, Mo T, Merzouki A, O’Shaughnessy, Oster C, Burke DS, Redfield RR, Birx DL, Cassol SA. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J of Virology 1995; 69:1868- 1877.
  114. Loomis LD, Deal CD, Kersey K, Burke DS, Redfield R R, Birx DL. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J of Acquir Immune Defic Syndr 1995: 10: 3-26.
  115. Lindstrom J, Smith KS, Skelton HG, Redfield R R, Alving BM, Wagner KF, Lupton GP. Increased anticardiolipin antibodies associated with the development of anetoderma in HIV-1 disease. Military Medical Consortium for the Advancement of Retroviral Research. International J of Dermatology. 1995; 34(6):408-415.
  116. Kaminiski RW, Loomis L, Levi NI, Amselem S, Kerey K, VanCott TC, Yogev A, Friedman D, Smith G, Wahren B, Redfield R R, Birx DL, Lowell GH. HIV peptide and protein antibody responses elicited by immunization with rgp160 formulated with proteosomes, alum and/or sub micron emulsions. Vaccine Research 1995; 4:189-206.
  117. Allen PJ, Gillespie DL, Redfield R R, Gomez ER. Lower extremity lymphedema caused by acquired immune deficiency syndrom-related Kaplsi’s sarcoma: case report and review of the literature. J of Vascular Surgery. 1995; 22(2): 178-181.
  118. VanCott TC, Kalyanaraman V, Earl P, Veit SCD, Burke DS, Redfield R R, Birx DL. Characterization of a soluble, oligomeric HIV-1 gp 120/gp41 protein as a candidate subunit vaccine. J of Immunological Methods 1995; 183: 103-117.
  119. VanCott TC, Polonis VR, Loomis LD, Redfield R R, Birx DL. Differential Role of V3- specific Antibodies in neutralization assays involving primary versus laboratory-adapted HIV-1. AIDS Research and Human Retroviruses 1995; 11: 1379-1391.
  120. Kim JH, McLinden RJ, Mosca JD, Vahey MT, Greene WC, Redfield R R. Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. J of Acquir Immune Defic Syndr. 1996; 12(4): 343-351
  121. Ratto S, Sitz KV, Scherer AM, Loomis LD, Cox JH, Redfield R R, Birx DL. CD4+T- lymphocyte lines developed from HIV-1 seropositive patients recognize different epitopes within the V3 loop. J of Acquir Immune Defic Syndr. 1996; 11(2):128.
  122. Michael NL, Kim ED, Loomis LD, VanCott TC, Burke DS, Redfield R R, Birx DL. Broadness of Seroreactivity to the V3 Loop of HIV-1 Correlates with the Emergence of V3 Genotypic Variation in Infected Patients.  AIDS. 1996; 10(2): 121-9.
  123. Kim JH, McLinden RJ, Mosca JD, Burke DS, Boswell RN, Birx DL, Redfield RR. Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones. J AIDS 1996; 12(4):329-42.
  124. Kim JH, Loveland JE, Sitz, Sylvia R, McLinden RJ, Tencer K, Davis K, Burke DS, Boswell RN, Redfield R R, Birx DL. Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: Interleukin 7 and Interleukin 12 differentially augment cellular proliferate responses to HIV. Clin Exp Immunol 1997;108(2):243-50.
  125. McLinden RJ, Lewis B, Michael NL, Redfield RR, Birx D, Kim JH. Correlation of tumor suppressor P53 RNA expression with human immunodeficiency virus disease in rapid and slow progressors. Journal of Human Virology 1997, 1(1):30-36
  126. Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis L, Smith G, Redfield R R, Amselem S, Birx DL. Nasal immunization with HIV gp 160 formulated with proteosomes, emulsomes and/or cholera toxin B subunit to enduce serum, intestinal, lung and vaginal antibodies. J Infect Disease 1997;175: 292-301.
  127. Sitz K, Loomis L, Ratto S, Kenner J, Sau P, Eckels K, Redfield R R, Birx D, Delayed-type hypersesitivity skin testing using third variable loop peptides identifies T-lymphocyte epitopes in HIV infected individuals. J Infect Disease 1997; 176: 1085-1089.
  128. Weinberg JM, Mysliwiec A, Turiansky GW, Redfield RR, James WD. Viral folliculitis; atypical presentations of herpes simplex, herpes zoster, and molluscum contagiosum. Archives of Dermatology 1997; 133 (8), 983-986
  129. Loomis L, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield R R, Robb ML, Wahren B, Sheppard HW, Birx DL. Correlation between humoral responses to HIV-1 envelope and disease progression in early-stage infection. J Infect Diseases. 1998; 178(5): 1306- 16.
  130. Ratto-Kim S, Sitz KV, Garner RP, Kim JH, Davis C, Aronson N, Ruiz N, Tencer K, Redfield R R, Birx Deborah. Repeated Immunization with Recombinant gp160 Human Immunodeficiency Virus (HIV) Envelope Protein in Early HIV-1 Infection: Evaluation of the T Cell Proliferative Response. J Infect Diseases 1999; 179 (2): 337 - 344.
  131. Margolis D, Heredia A, Gaywee J, Drusano G, Oldach D, Redfield R R Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J AIDS. 1999; 21:362-370.
  132. Heredia A, Margolis D, Oldach D, Hazen R, Nhut L, Redfield R . Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J AIDS. 1999; 22:406-412.
  133. Sandstrom E, Wahren B, Nordic VAC-04 Study Group (Redfield R R). Therapeutic immunization with recombinant gp160 in HIV-1 infection: a randomized double-blind placebo- controlled trial. Lancet. 1999; 353:1735-42.
  134. Bratt G, Eriksson LE, Sandstrom E, Gilljam G, Hinkula J, Albert J, Redfield R R, Wahren B. Long term immunotherapy in HIV infection, combined with short term antiretroviral treatment. International J STD & AID., 1999;10:514-521.
  135. Cox JH, Garner P, Redfield R R, Aronson N, Davis C, Ruiz N, Birx DL. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. AIDS Research and Human Retroviruses. 1999; 15: 847-854.
  136. Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, Redfield RR. Efficacy testing of recombinant human  immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis. 2000; 181:881-9.
  137. Heredia A, Davis C, Redfield RR. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, Resveratrol. J AIDS. 2000; 25(3):246-255.
  138. Cocchi F, DeVico AL, Yarchoan R, Redfield RR, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, Gallo RC. Higher macrophage inflammatory protein (MIP)-1α and MIP-1β levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.   PNAS Dec 5 2000; 97:25; 13812-13817
  139. Keay S, Oldach D, Redfield RR, Bartlett S. Organ transplantation in the HIV-infected patient. Current Opinion in Organ Transplantation 2000; 5(3), 217-223
  140. Davis C, Heredia A, Le N, Dominique JK, Redfield RR. Differential Human Immunodeficiency Virus-suppressive Activity of Reverse Transcription Inhibitors in Resting and Activated Peripheral Blood Lymphocytes. JHV. May/June 2001;4(3):113-22.
  141. Dybul M, Bolan R, Condoluci D, Cox-Iyamu R, Redfield RR, Hallahan C, Folino M, Sathasivam K, Weisberg M, Andrews M, Hidalgo B, Vasquez J, Fauci A. Evaluation of Initial CD4 T Cell Counts in Individuals with Newly Diagnosed Human Immunodeficiency Virus Infection, by Sex and Race, in Urban Settings. J. Infect. Dis. 2002;185:1818-21.
  142. Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E, Reardon E, Zella D, Redfield RR. Induction of G1 Cell Cycle Arrest in Peripheral Blood Mononuclear Cells Results in Increased Extracellular Levels of RANTES, MIP-1α and MIP-1β: a Strategy to Inhibit Replication of R5 strains of HIV-1. Proc. Nat’l. Acad. Sci. USA, 2003;100:4179-4184.
  143. Gilliam B, Redfield RR. Therapeutic HIV Vaccines. Curr Top Med Chem. 2003: 3(13): 1536- 1553.
  144. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, Lobashevsky A, Redfield RR, Schweitzer E, Heredia A, Reardon E, Davis C, Bentlejewski C, Fung J, Shapiro R, Zeevi A. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003: 17: 77-88.
  145. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes downregulation of CCR5 and accumulation of anti-HIV ß - chemokines: an approach to suppress R5 strains of HIV-1. Proc. Nat’l Acad. Sci. USA, 2003;100:10411-10416.
  146. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD.  Association Between Longer Duration HIV Suppressive Therapy and Partial Recovery V Gamma 2 T Cell Receptor Repertoire, J. Infect. Dis. 2004;189(8):1482-6.
  147. Ratto-Kim S, Garner R, Kim J, Jagodzinksi L, Nelson M, Paris R, Redfield RR, Birx D. Prospective Analysis of HIV-1 Specific and Recall Antigen Proliferative Responses and Clinical Outcomes in a HIV-1 Seropositive Cohort. J Infect Dis. 2004:189(11):1988-95.
  148. Ruckwardt TJ, Tikhonov I, Berg S, Hatfield GS, Chandra A, Chandra P, Gilliam B, Redfield RR, Gallo RC, Pauza CD. Sequence Variation within the Dominant Amino Terminus Epitope Affects Antibody Binding and Neutralization of Human Immunodeficiency Virus Type 1 Tat Protein. J Virol 2004;78(23):13190-6.
  149. Amoroso, Anthony; Spencer, Derek E; Redfield, RR. Improving on success: what treating the urban poor in America can teach us about improving antiretroviral programmes in Africa. AIDS, 18 Supplement 3:S39-S43, June 2004.
  150. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield RR. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti- HIV activity. J PharSci 2004; 93(10):2448-57.
  151. Li H, Song H, Heredia A, Le N, Redfield RR, Lewis GK, Wang LX. Synthetic bivalent CD4- mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Bioconjugate Chemistry 2004; 15(4), 783-789
  152. Heredia A, Davis, CE Jr, Amoroso A, Taylor G, Le N, Bamba D, Redfield RR. In Vitro Suppression of latent HIV-1 activation by Vitamin E: potential clinical implications.  AIDS 2005, 20;19(8):836-7.
  153. Reisler R, Redfield RR, Murphy R, Parker R. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies. J Acquir Immune Defic Syndr 06/01/2005 Vol: 39, No: 2 pp 159-66.
  154. Alonso Heredia, Charles Davis, Douty Bamba, Nhut Le, Muhammad Y. Gwarzo, Mariola Sadowska, Robert C. Gallo, Robert R. Redfield Indirubin-3’-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 2005, 19:2087-2095.
  155. Bruce L. Gilliam, Robert R. Redfield Approaches to antiretroviral therapy in China. Cell Research, 2005;15 (11-12): 895-902.
  156. Bruce L. Gilliam, Robert R. Redfield, Richard Y. Zhao, Robert C. Gallo. Commentary on Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Research, 2005;15 (11-12): 850-851.
  157. Wang J, Le N, Heredia A, Song H, Redfield RR, Wang LX. Modification and structure activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120.  Organic and Biomolecular Chemistry 2005; 3 (9), 1781-1786
  158. Bruce L. Gilliam, Kirk M. Chan Tack, Roula B. Qaqish, Richard A. Rode, Lori E. Fantry, Robert R. Redfield. Successful Treatment with Atazanavir and Lopinavir/Ritonavir Combination Therapy in Protease Inhibitor-Susceptible and Protease Inhibitor-Resistant HIV- Infected Patients. AIDS Patient Care and STDs, 2006;Vol 20, No 11.
  159. Chan Tack KM, Ahuja N, Weinman EJ, Wali RK, Uche A, Greisman LA, Drachenberg C, Hawkins PN, Redfield RR.. Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV infected patient. The American Journal of the Medical Sciences 2006; 332 (6), 364-367
  160. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC,  Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian M. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha infusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antiviral Therapy 2006; 11 (1) 35
  161. Richard Elion, Calvin Cohen, Edwin DeJesus, Robert Redfield, Joseph Gathe, Ricky Hsu, Linda Yau, Lisa Ross, Belinda Ha, E. Randall Lanier, Trevor Scott. Once-Daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Subjects: A 48-Week Pilot Study. HIV Clin Trials 2006; 7(6):324-333.
  162. Heredia A, Gilliam B, DeVico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, and Redfield, RR.  CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS 2007;21 (10): 1317-22.
  163. Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, DeVico A, Melikyan G, Gallo RC, Redfield RR. Rapamycin reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) Against R5 Strains of Human Immunodeficiency Virus Type 1 in Vitro. Antimicrobial Agents and Chemotherapy, July 2007, p. 2489-2496.
  164. Sajadi M, Heredia A, Le N, Constantine N, Redfield R. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007, 21: 517-519.
  165. Gilliam BL, Heredia A, DeVico A, Le N, Bamba D, Bryant JL, Pauza CD, and Redfield RR. Rapamycin reduces CCR5 m-RNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007; 21(15); 2108-10.
  166. Gilliam BL, Sajadi MM, Amoroso A, Davis CE, Cleghorn FR, Redfield RR. Tenofovir and Abacavir combination therapy: lessons learned from an urban population. AIDS Patient Care and STDs 2007; 21 (4) 240-246
  167. Lum H, Isichei C, Isichei-Wakili M, Redfield RR. Expansion of HIV-1 screening and antiretroviral screening programs in a resource poor setting: results from a faith based organization in Jos, Plateau State, Nigeria. African Health Sciences 2007; 7(2)
  168. Riedel DJ, Gonzalez-Cuyar LF, Zhao F, Redfield RR, Gilliam BL. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect  Dis 2008; 8:261-267.
  169. Redfield RR, Morrow JS. Combination Antiretroviral Therapy with Tenofovir, Emtricitabine or Lamivudine, and Nevirapine. CID 2008:47 (1 October).
  170. Fätkenheuer G, Nelson M, Laszzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE 1 and MOTIVATE 2 Study Teams (Redfield RR). Subgroup Analysis of Maraviroc in previously treated R5 HIV-Infection. N Engl J Med. 2008 Oct 2, 359(14):1442-55.
  171. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, MOTIVATE Study Teams (Redfield RR). Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 2; 359(14):1429- 41.
  172. Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D’Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.  Antiviral Activity of Single Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV Infected Adults. J Infect Dis. 2008 Nov 1, 198(9):1345-1352.
  173. Heredia A, Latinovic O, Gallo R, Melikyan G, Reitz M, Le N, Redfield R. Reduction of CCR5 with low dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug resistant HIV-1. PNAS 2008; Vol 105, No 51.
  174. Yadav A, Fitzgerald P, Sajadi M, Gilliam B, Lafferty M, Redfield R, Reid W. Increased expression of suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology (2009), doi:10.1016/j.virol.2008.11.039.
  175. Y Guan, MM Sajadi, R Kamin-Lewis, T Fouts, A Dimitrov, Z Zhang, R Redfield, AL DeVico, R Gallo, GK Lewis. Humoral Immunity against Conserved Epitopes of the HIV-1 Envelope Protein Archived in Memory B cells in Natural Viral Suppressors: Discordance with Plasma Antibodies. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7. PMID: 19225108
  176. MM Sajadi, NT Constantine, DL Mann, M Charurat, E Dadzan, P Kadlecik, RR Redfield. Epidemiologic Characteristics and Natural History of HIV-1 Natural Viral Suppressors. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):403-8. PMCID: PMC2697612
  177. Riedel DJ, Sajadi MM, Armstrong CL, Cummings JS, Cairo C, Redfield RR, Pauza CD. Natural Viral Suppressors of HIV-1 Have An Unique Capacity to Maintain γδ T Cells. AIDS. 2009 Jul 15 23:1955-1964
  178. Ross L, Elion R, Lanier R, Dejesus E, Cohen C, Redfield R, Gathe J, Hsu R, Yau L, Paulsen  D, Ha B. Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263). AIDS Research and Human Retroviruses, 2009, Vol. 25, Number 7.
  179. Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR. Rapamycin enhances Aplaviroc anti-HIV activity: Implications for the clinical development of novel CCR5 antagonists. J Antiviral 2009, 83: 86-89.
  180. Etienne M, Hossain M, Redfield R, Stafford K, Amoroso A. Indicators of Adherence to Antiretroviral Therapy Treatment Among HIV/AIDS Patients in 5 African Countries. Journal of the International Association of Physicians in AIDS Care 2009: 9 (2) 98-103
  181. Etienne M, Burrows L, Osotimehin B, Macharia T, Hossain B, Redfield R, Amoroso A. Situational Analysis of Varying Models of Adherence Support and Lost to Follow Up Rates; Findings From 27 Treatment Facilities in Eight Resource Limited Countries. Tropical Medicine and International Health, 2010 Vol. 15, Suppl I, 76-81.
  182. Sajadi MM, Shakeri N, Talwani R, Redfield RR. Hepatitis C Infection in HIV-1 Natural Viral Suppressors. AIDS 2010 May 12
  183. Gilliam B, Riedel D, Redfield R. Clinical Use of CCR5 Inhibitors in HIV and Beyond. Journal of Translational Medicine 2010, 9(Suppl 1):S9
  184. Sajadi MM, Redfield RR. Long-term nonprogressive disease among individuals with untreated HIV infection (letter to the editor). JAMA 2010; 304 (16); 1784-1786
  185. Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke J, Redfield R, Heredia A. Synergistic Inhibition of R5 HIV-1 by Maraviroc and CCR5 Antibody HGS004 in Primary Cells: Implications for Treatment and Prevention. AIDS, 2011: 1;25(9):1232-5
  186. Marinucci F, Medina-Moreno S, Paterniti AD , Wattleworth M, Redfield RR  Decentralization of CD4 testing in resource limited settings: 7 years of experience in 6 African countries. Cytometry: Part A, 2011 May;79(5):368-74.
  187. Sajadi MM, Shakeri N, Talwani R, Howell CD, Pakyz R, Redfield RR, Parsa A. IL28B genotype does not correlate with HIV control in African Americans. Clin Transl Sci. 2011 Aug 4 (4):282-4
  188. Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis G, Redfield RR. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. JAIDS 2011; 57 (1) 9
  189. Pauza CD, Riedel D, Gilliam B, Redfield RR. Targeting T Cells for Immunotherapy of HIV Disease. Future Virology. 2011 6(1), 73-84
  190. Majid A, Redfield RR, Gilliam BL. The Use of Pre-Exposure Treatments for HIV Prophylaxis. HIV/AIDS Research and Palliative Care. 2012:4 17-28.
  191. Sajadi MM, Lewis GK, Seaman M, Guan Y, Redfield RR, DeVico A. Signature Biochemical Properties of Broadly Cross-Reactive HIV-1 Neutralizing Antibodies in Human Plasma. J Virology, 2012; May; Vol. 86 (9), pp. 5014-25
  192. Cocchi F, DeVico A, Lu W, Popovic M, Latinovic O, Sajadi M, Redfield RR, Lafferty M, Galli M, Garzino Demo A, Gallo RC. Soluble Factors From T Cells Inhibiting X4 Strains of HIV are a Mixture of β Chemokines and RNases. PNAS 2012, Vol 109, no. 14, p. 5411-5416
  193. Boudova S, Li H, Sajadi MM, Redfield RR, Pauza CD. Impact of Persistent HIV Replication on CD4 Negative Vγ2Vδ2 T Cells. JID 2012; 205:1448-55.
  194. Amoroso A, Etienne-Mesubi M, Edozien A, Ojoo S, Sheneberger R, Obiefune M, Hossian M, Stafford K, Redfield RR. Treatment Outcomes of Recommended First Line Antiretroviral Regimens in Resource Limited Clinics. JAIDS 2012-Volume 60, Issue 3, p 314-320
  195. Sajadi MM, Pulijala R, Redfield RR, Talwani R. Chronic Immune Activation and Decreased CD4 Cell Counts Associated with Hepatitis C Infection in HIV-1 Natural Viral Suppressors. AIDS 2012; Vol 26, Issue 15, p 1879-1884.
  196. Hicks C, Clay P, Redfield RR, Lalezari J, Liporace R, Schneider S, Sension M, McRae M, Laurent JP. Safety, Tolerability, and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral Experienced, HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses 2013, Vol 29, No 2, p.250-255
  197. Marinucci F, Manyazewal T, Paterniti A, Medina Moreno S, Wattleworth M, Hagembe J, Redfield RR. Impact of Horizontal Approach in Vertical Program: Continuous Quality Improvement of Malaria and Tuberculosis Diagnostic Services at Primary Level Medical Laboratories in the Context of HIV Care and Treatment Program in Ethiopia. AM J. Trop. Med. Hyg. 2013; 88(3), pp.547-551
  198. Riedel DJ, Mwanji EIW, Fantry LE, Alexander C, Hossain MB, Pauza CD, Redfield RR, Gilliam BL. High cancer-related mortality in an urban, predominantly African-American, HIV- infected population. AIDS 2013;27:1109-1117.
  199. Eyzaguirre L, Charurat M, Redfield RR, Blattner W, Carr J, Sajadi M. Elevated Hypermutation Levels in HIV-1 Natural Viral Suppressors. Virology, 2013; 443:306-312
  200. Marinucci F, Majigo M, Wattleworth M, Paterniti A, Hossain M, Redfield RR. Factors Affecting Job Satisfaction and Retention of Medical Laboratory Professionals in Seven Countries of Sub Saharan Africa. Human Resources for Health 2013, 11:38.
  201. Boudova S, Li H, Sajadi MM, Redfield RR, Cairo C, Pauza DP. Reply to Hartjen et al (letter reply). Journal of Infectious Diseases 2013; 208 (1), 184
  202. Sajadi MM, Redfield RR, Talwani R. Altered T Cell Subsets in HIV-1 Natural Viral Suppressors (Elite Controllers) With Hepatitis C Infection. AIDS, 2013 May 8, 27: 1989-1995, PMID: 23660578
  203. Heredia A, Davis CE, Reitz MS, Le N, Wainberg MA, Foulke JS, Wang L, Redfield RR. Targeting of the Purine Biosynthesis Host Cell Pathway Enhances the Activity of Tenofovir Against Sensitive and Drug Resistant HIV-1. J Infect Dis, 2013 Dec; Vol 208 (12), pp. 2085-94
  204. Heredia A, Davis C, Amin M, Le N, Wainberg MA, Oliveira M, Deeks S, Wang L, Redfield RR. Targeting Host Nucleotide Biosynthesis with Resveratrol Inhibits Emtricitabine Resistant HIV-1.  AIDS, 2014 January 28, 28:317-323
  205. Heredia A, Natesan S, Nhut L, Medina Moreno S, Zapata J, Reitz M, Bryant J, Redfield RR. Indirubin 3’-monoxime, from a Chinese Traditional Herbal Formula, Suppresses Viremia in Humanized Mice Infected With Multidrug-resistant HIV AIDS Research and Human Retroviruses, AIDS Research and Human Retroviruses 2014, Vol 30, No 5, p. 403-406
  206. Osinusi-Adekanmbi O, Stafford K, Ukpaka A, Salami D, Ajayi S, Ndembi N, Abimiku A, Nwizu C, Gilliam B, Redfield RR, Amoroso A. Long Term Outcome of Second Line Antiretroviral Therapy in Resource Limited Settings. Journal of the International Association of Providers of AIDS Care (JIAPAC) 2014 March 25, published online. DOI 10.1177/2325957414527167
  207. Alexander CS, Pappas G, Henley Y, Kaiza Kangalawe A, Olusegun Oyebola F, Obiefune M, Nwene E, Stanis-Ezeobi W, Enejoh V, Nwizu C, Nwandu A, Memiah P, Etienne-Mesubi M, Oni B, Amoroso A, Redfield RR. Pain Management for Persons Living With HIV Disease: Experience With Interprofessional Education in Nigeria. American Journal of Hospice Medicine. DOI 10:1177/1049909114527153
  208. Narayanan S, Townsend K, Macharia T, Majid A, Nelson A, Redfield RR, Kottilil S, Talwani R, Osinusi A. Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C.  Hepatology International, October 2014, Vol 8, Issue 4, pp 560-566


Robert R. Redfield


  • :(410) 706-4613

    • DEPARTMENTDepartment of Medicine
      University of Maryland